Literature DB >> 7595753

Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

S Sugimoto1, Y L Yamamoto, S Nagahiro, M Diksic.   

Abstract

The present study was designed to find the reliable parameter(s) for the detection of early neurotoxicity following intracarotid (IC) administration of cisplatin. IC administration was performed for 60 minutes in female Wistar rats derived into four groups according to the dose given (1 mg, 1.2 mg, and 1.5 mg of cisplatin, and normal saline in control rats). Blood-brain barrier (BBB) permeability and local cerebral blood flow (LCBF) were measured by a double-tracer autoradiography technique using 1-[14C]-alpha-aminoisobutyric acid (14C-AIB) and 4-[18F] fluoroantipyrine (18F-FAP), respectively. Blood chemistry and neuropathology were also examined. BBB permeability was increased only on the ipsilateral side. This increase was dose-dependent, preceded the brain necrosis, and was statistically significant in the hypothalamus (1.2 mg group), auditory cortex and caudoputamen (1.5 mg group). Renal dysfunction was often observed. The changes in the LCBF did not occur until brain necrosis was noticeable. These findings demonstrate that the increase in the BBB permeability provides a sensitive and reliable indication of an early toxicity to brain tissue following IC administration of cisplatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595753     DOI: 10.1007/BF01052839

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  The nephrotoxic effects of cis-diammine-dichloroplatinum (II) (NSC-119875) in male F344 rats.

Authors:  J M Ward; K A Fauvie
Journal:  Toxicol Appl Pharmacol       Date:  1976-12       Impact factor: 4.219

2.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

3.  Intravascular streaming and variable delivery to brain following carotid artery infusions in the Sprague-Dawley rat.

Authors:  S C Saris; D C Wright; E H Oldfield; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1988-02       Impact factor: 6.200

4.  Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.

Authors:  R J Kociba; S D Sleight
Journal:  Cancer Chemother Rep       Date:  1971-02

5.  An improved approach for measurement of regional cerebral rate constants in the deoxyglucose method with positron emission tomography.

Authors:  A Kato; M Diksic; Y L Yamamoto; S C Strother; W Feindel
Journal:  J Cereb Blood Flow Metab       Date:  1984-12       Impact factor: 6.200

6.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; A A Hart; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1984-03

7.  Use of short-lived 18F and long-lived 14C in double tracer autoradiography for simultaneous measurement of LCBF and LCGU.

Authors:  K Sako; A Kato; M Diksic; L Y Yamamoto
Journal:  Stroke       Date:  1984 Sep-Oct       Impact factor: 7.914

8.  Intra-arterial cisplatin for the treatment of malignant gliomas.

Authors:  H B Newton; M A Page; L Junck; H S Greenberg
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

9.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Etoposide-induced blood-brain barrier disruption. Effect of drug compared with that of solvents.

Authors:  M K Spigelman; R A Zappulla; J Johnson; S J Goldsmith; L I Malis; J F Holland
Journal:  J Neurosurg       Date:  1984-10       Impact factor: 5.115

View more
  11 in total

1.  Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

Authors:  P S Rangi; W J Partridge; E S Newlands; A D Waldman
Journal:  Neuroradiology       Date:  2005-07-05       Impact factor: 2.804

2.  Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.

Authors:  Takahiro Maeda; Eiji Kikuchi; Kazuhiro Matsumoto; Satoshi Yazawa; Jun Hagiuda; Akira Miyajima; Ken Nakagawa; Hirokazu Fujiwara; Haruhiko Hoshino; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2010-03-30       Impact factor: 3.402

3.  Cortical thinning and altered functional brain coherence in survivors of childhood sarcoma.

Authors:  Charlotte Sleurs; Jeroen Blommaert; Dafnis Batalle; Marjolein Verly; Stefan Sunaert; Ron Peeters; Jurgen Lemiere; Anne Uyttebroeck; Sabine Deprez
Journal:  Brain Imaging Behav       Date:  2021-04       Impact factor: 3.978

4.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

Review 5.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

6.  Posterior Reversible Encephalopathy Syndrome Secondary to R-CHOP Chemotherapy Regimen.

Authors:  Selim Jennane; El Mehdi Mahtat; Mounir Ababou; Hicham El Maaroufi; Kamal Doghmi
Journal:  Cureus       Date:  2022-05-14

7.  Developing central nervous system and vulnerability to platinum compounds.

Authors:  G Bernocchi; M G Bottone; V M Piccolini; V Dal Bo; G Santin; S A De Pascali; D Migoni; F P Fanizzi
Journal:  Chemother Res Pract       Date:  2011-02-15

8.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006

Review 9.  Chemotherapy and the pediatric brain.

Authors:  Chrysanthy Ikonomidou
Journal:  Mol Cell Pediatr       Date:  2018-11-06

10.  Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer.

Authors:  Eiichi Katada; Akira Mitsui; Shigeru Sasaki; Norihiko Uematsu; Chise Anan
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.